The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

NCT06160362 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

20

Enrollment

OTHER_GOV

Sponsor class

Conditions

Non-hodgkin Lymphoma,B Cell

Interventions

BIOLOGICAL: CART-19 and 20 cells
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

Henan Cancer Hospital